Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2022

08.06.2022

Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases: from Basic Research to Clinical Trials

verfasst von: Pengpeng Cao, Ming Yang, Christopher Chang, Haijing Wu, Qianjin Lu

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Germinal center (GC) reaction greatly contributes to the humoral immune response, which begins in lymph nodes or other secondary lymphoid organs after follicular B cells are activated by T-dependent antigens. The GCs then serve as a platform for follicular B cells to complete clonal expansion and somatic hypermutation and then interact with follicular dendritic cells (FDC) and follicular helper T cells (Tfh). Through the interaction between the immune cells, significant processes of the humoral immune response are accomplished, such as antibody affinity maturation, class switching, and production of memory B cells and plasma cells. Cell positioning during the GC reaction is mainly mediated by the chemokine receptors and lipid receptors, which both belong to G protein-coupled receptors (GPCRs) family. There are some orphan GPCRs whose endogenous ligands are unclear yet contribute to the regulation of GC reaction as well. This review will give an introduction on the ligands and functions of two types of GC-relating GPCRs—chemokine receptors like CXCR4 and CXCR5, as well as emerging de-orphanized GPCRs like GPR183, GPR174, and P2RY8. The roles these GPCRs play in several antibody-mediated autoimmune skin diseases will be also discussed, including systemic lupus erythematosus (SLE), pemphigus, scleroderma, and dermatomyositis. Besides, GPCRs are excellent drug targets due to the unique structure and vital functions. Therefore, this review is aimed at providing readers with a focused knowledge about the role that GPCRs play in GC reaction, as well as in provoking the development of GPCR-targeting agents for immune-mediated diseases besides autoimmune diseases.
Literatur
1.
Lee A, Bannan JL, Adams MJ et al (2017) Expression of CCR6 on B cells in systemic lupus erythematosus patients[J]. Clin Rheumatol 36(6):1453–1456PubMedCrossRef
2.
Demoor T, Bracke KR, Maes T et al (2009) Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis[J]. Eur Respir J 34(2):405–416PubMedCrossRef
3.
Anderson MW, Zhao S, Ai WZ et al (2010) C-C chemokine receptor 1 expression in human hematolymphoid neoplasia[J]. Am J Clin Pathol 133(3):473–483PubMedCrossRef
4.
5.
Koscielny G, An P, Carvalho-Silva D et al (2017) Open Targets: a platform for therapeutic target identification and validation[J]. Nucleic Acids Res 45(D1):D985–D994PubMedCrossRef
6.
Cabral-Marques O, Marques A, Giil LM et al (2018) GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis[J]. Nat Commun 9(1):5224PubMedPubMedCentralCrossRef
7.
Groves A, Kihara Y, Jonnalagadda D et al (2018) A functionally defined in vivo astrocyte population identified by c-Fos activation in a mouse model of multiple sclerosis modulated by S1P signaling: immediate-early astrocytes (ieAstrocytes)[J]. eNeuro 5(5)
8.
Li E, Shan H, Chen L et al (2019) OLFR734 Mediates glucose metabolism as a receptor of asprosin[J]. Cell Metab 30(2):319–328PubMedCrossRef
9.
Sharma G, Hu C, Staquicini DI et al (2020) Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes[J]. Sci Transl Med 12(528)
10.
Palacios JM, Pazos A, Hoyer D (2017) A short history of the 5-HT(2C) receptor: from the choroid plexus to depression, obesity and addiction treatment[J]. Psychopharmacology 234(9–10):1395–1418PubMedCrossRef
11.
12.
Chang W, Tu CL, Jean-Alphonse FG et al (2020) PTH hypersecretion triggered by a GABA(B1) and Ca(2+)-sensing receptor heterocomplex in hyperparathyroidism[J]. Nat Metab 2(3):243–255PubMedPubMedCentralCrossRef
13.
Abdel-Magid AF (2019) Treatment of diabetes, obesity, dyslipidemia, and related disorders with GPR119 agonists[J]. ACS Med Chem Lett 10(1):14–15PubMedCrossRef
14.
Celorrio M, Rojo-Bustamante E, Fernández-Suárez D et al (2017) GPR55: a therapeutic target for Parkinson’s disease?[J]. Neuropharmacology 125:319–332PubMedCrossRef
15.
Planell N, Masamunt MC, Leal RF et al (2017) Usefulness of transcriptional blood biomarkers as a non-invasive surrogate marker of mucosal healing and endoscopic response in ulcerative colitis[J]. J Crohns Colitis 11(11):1335–1346PubMedPubMedCentralCrossRef
16.
Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity[J]. Annu Rev Immunol 32:659–702PubMedCrossRef
17.
Schulz O, Hammerschmidt SI, Moschovakis GL et al (2016) Chemokines and chemokine receptors in lymphoid tissue dynamics[J]. Annu Rev Immunol 34:203–242PubMedCrossRef
18.
Friedman SL, Ratziu V, Harrison SA et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology 67(5):1754–1767PubMedCrossRef
19.
Sato T, Coler-Reilly A, Yagishita N et al (2018) Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy[J]. N Engl J Med 378(6):529–538PubMedCrossRef
20.
Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial[J]. Lancet Oncol 19(9):1192–1204PubMedCrossRef
21.
Schott AF, Goldstein LJ, Cristofanilli M et al (2017) Phase Ib Pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer[J]. Clin Cancer Res 23(18):5358–5365PubMedPubMedCentralCrossRef
22.
Nakajima C, Mukai T, Yamaguchi N et al (2002) Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation[J]. Eur J Immunol 32(6):1792–1801PubMedCrossRef
23.
Groom JR, Richmond J, Murooka TT et al (2012) CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation[J]. Immunity 37(6):1091–1103PubMedPubMedCentralCrossRef
24.
Campbell DJ, Kim CH, Butcher EC (2001) Separable effector T cell populations specialized for B cell help or tissue inflammation[J]. Nat Immunol 2(9):876–881PubMedCrossRef
25.
26.
Turpin D, Furudoi A, Parrens M et al (2018) Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications[J]. Clin Immunol 197:130–138
27.
Bier J, Rao G, Payne K et al (2019) Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4(+) T cells[J]. J Allergy Clin Immunol 144(1):236–253PubMedPubMedCentralCrossRef
28.
Ottaviano G, Gerosa J, Santini M et al (2020) A prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates humoral dysregulation in children with Down Syndrome[J]. J Clin Immunol 40(3):447–455PubMedCrossRef
29.
Kawaguchi N, Zhang TT, Nakanishi T (2019) Involvement of CXCR4 in normal and abnormal development[J]. Cells 8(2)
30.
Allen CD, Ansel KM, Low C et al (2004) Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5[J]. Nat Immunol 5(9):943–952PubMedCrossRef
31.
Weber TS (2018) Cell cycle-associated CXCR4 expression in germinal center B cells and its implications on affinity maturation[J]. Front Immunol 9:1313PubMedPubMedCentralCrossRef
32.
Pak HK, Nam B, Lee YK et al (2018) Human plasmablast migration toward CXCL12 requires glucose oxidation by enhanced pyruvate dehydrogenase activity via AKT[J]. Front Immunol 9:1742PubMedPubMedCentralCrossRef
33.
Jandl C, Liu SM, Cañete PF et al (2017) IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2[J]. Nat Commun 8:14647PubMedPubMedCentralCrossRef
34.
Unger PA, Lighaam LC, Vermeulen E et al (2020) Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses[J]. Eur J Immunol
35.
Vanderleyden I, Fra-Bido SC, Innocentin S et al (2020) Follicular regulatory T cells can access the germinal center independently of CXCR5[J]. Cell Rep 30(3):611–619PubMedPubMedCentralCrossRef
36.
Shen E, Rabe H, Luo L et al (2019) Control of germinal center localization and lineage stability of follicular regulatory T cells by the Blimp1 transcription factor[J]. Cell Rep 29(7):1848–1861PubMedPubMedCentralCrossRef
37.
Denton AE, Innocentin S, Carr EJ et al (2019) Type I interferon induces CXCL13 to support ectopic germinal center formation[J]. J Exp Med 216(3):621–637PubMedPubMedCentralCrossRef
38.
39.
40.
Gu-Trantien C, Migliori E, Buisseret L et al (2017) CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer[J]. JCI Insight 2(11)
41.
42.
Tarnowski M, Liu R, Wysoczynski M et al (2010) CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells[J]. Eur J Haematol 85(6):472–483PubMedCrossRef
43.
Tarnowski M, Grymula K, Liu R et al (2010) Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts[J]. Mol Cancer Res 8(10):1328–1343PubMedPubMedCentralCrossRef
44.
Szpakowska M, Dupuis N, Baragli A et al (2016) Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7[J]. Biochem Pharmacol 114:14–21PubMedCrossRef
45.
Humpert ML, Pinto D, Jarrossay D et al (2014) CXCR7 influences the migration of B cells during maturation[J]. Eur J Immunol 44(3):694–705PubMedCrossRef
46.
Boldajipour B, Mahabaleshwar H, Kardash E et al (2008) Control of chemokine-guided cell migration by ligand sequestration[J]. Cell 132(3):463–473PubMedCrossRef
47.
Wang H, Beaty N, Chen S et al (2012) The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12[J]. Blood 119(2):465–468PubMedPubMedCentralCrossRef
48.
Kuang L, Wu J, Su N et al (2020) FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice[J]. Ann Rheum Dis 79(1):112–122PubMedCrossRef
49.
Zabel BA, Lewén S, Berahovich RD et al (2011) The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells[J]. Mol Cancer 10:73PubMedPubMedCentralCrossRef
50.
Daniel SK, Seo YD, Pillarisetty VG (2020) The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies[J]. Semin Cancer Biol 65:176–188PubMedCrossRef
51.
52.
53.
Li S, Fong KW, Gritsina G et al (2019) Activation of MAPK Signaling by CXCR7 leads to enzalutamide resistance in prostate cancer[J]. Cancer Res 79(10):2580–2592PubMedPubMedCentralCrossRef
54.
Becker JH, Gao Y, Soucheray M et al (2019) CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC[J]. Cancer Res 79(17):4439–4452PubMedPubMedCentralCrossRef
55.
Reimer D, Lee AY, Bannan J et al (2017) Early CCR6 expression on B cells modulates germinal centre kinetics and efficient antibody responses[J]. Immunol Cell Biol 95(1):33–41PubMedCrossRef
56.
Kochi Y, Okada Y, Suzuki A et al (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility[J]. Nat Genet 42(6):515–519PubMedCrossRef
57.
Suan D, Kräutler NJ, Maag J et al (2017) CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity[J]. Immunity 47(6):1142–1153PubMedCrossRef
58.
Lin YL, Ip PP, Liao F (2017) CCR6 Deficiency impairs IgA production and dysregulates antimicrobial peptide production, altering the intestinal flora[J]. Front Immunol 8:805PubMedPubMedCentralCrossRef
59.
Albright AR, Kabat J, Li M et al (2019) TGFβ signaling in germinal center B cells promotes the transition from light zone to dark zone[J]. J Exp Med 216(11):2531–2545PubMedPubMedCentralCrossRef
60.
Ryota H, Ishida M, Satoi S et al (2019) Clinicopathological and immunological features of follicular pancreatitis - a distinct disease entity characterised by Th17 activation[J]. Histopathology 74(5):709–717PubMedCrossRef
61.
Bonami RH, Nyhoff LE, McNitt DH et al (2020) T-B Lymphocyte interactions promote type 1 diabetes independently of SLAM-associated protein[J]. J Immunol
62.
63.
Hashizume-Takizawa T, Kobayashi R, Tsuzukibashi O et al (2019) CCR7-deficient mice exhibit a delayed antigen-specific mucosal IgA antibody response to an oral recombinant Salmonella strain[J]. Pathog Dis 77(3)
64.
Liu X, Chen X, Zhong B et al (2014) Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development[J]. Nature 507(7493):513–518PubMedPubMedCentralCrossRef
65.
66.
Birkenbach M, Josefsen K, Yalamanchili R et al (1993) Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors[J]. J Virol 67(4):2209–2220PubMedPubMedCentralCrossRef
67.
68.
69.
Gatto D, Paus D, Basten A et al (2009) Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses[J]. Immunity 31(2):259–269PubMedCrossRef
70.
Gatto D, Wood K, Brink R (2011) EBI2 operates independently of but in cooperation with CXCR5 and CCR7 to direct B cell migration and organization in follicles and the germinal center[J]. J Immunol 187(9):4621–4628PubMedCrossRef
71.
Suan D, Nguyen A, Moran I et al (2015) T follicular helper cells have distinct modes of migration and molecular signatures in naive and memory immune responses[J]. Immunity 42(4):704–718PubMedCrossRef
72.
Li J, Lu E, Yi T et al (2016) EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells[J]. Nature 533(7601):110–114PubMedPubMedCentralCrossRef
73.
Niss AK, Barington L, Benned-Jensen T et al (2017) EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies[J]. Blood 129(7):866–878CrossRef
74.
Feldman S, Kasjanski R, Poposki J et al (2017) Chronic airway inflammation provides a unique environment for B cell activation and antibody production[J]. Clin Exp Allergy 47(4):457–466PubMedPubMedCentralCrossRef
75.
Barnes MJ, Li CM, Xu Y et al (2015) The lysophosphatidylserine receptor GPR174 constrains regulatory T cell development and function[J]. J Exp Med 212(7):1011–1020PubMedPubMedCentralCrossRef
76.
77.
Zhu M, Li C, Song Z et al (2020) The increased marginal zone B cells attenuates early inflammatory responses during sepsis in Gpr174 deficient mice[J]. Int Immunopharmacol 81:106034
78.
Chu X, Shen M, Xie F et al (2013) An X chromosome-wide association analysis identifies variants in GPR174 as a risk factor for Graves’ disease[J]. J Med Genet 50(7):479–485PubMedCrossRef
79.
Yue J, Zhao X (2020) GPR174 suppression attenuates retinopathy in angiotensin II (Ang II)-treated mice by reducing inflammation via PI3K/AKT signaling[J]. Biomed Pharmacother 122:109701
80.
Konkel JE, Zhang D, Zanvit P et al (2017) Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses[J]. Immunity 46(4):660–674PubMedCrossRef
81.
Zhao R, Chen X, Ma W et al (2020) A GPR174-CCL21 module imparts sexual dimorphism to humoral immunity[J]. Nature 577(7790):416–420PubMedCrossRef
82.
Lohr JG, Stojanov P, Lawrence MS et al (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing[J]. Proc Natl Acad Sci U S A 109(10):3879–3884PubMedPubMedCentralCrossRef
83.
Muppidi JR, Schmitz R, Green JA et al (2014) Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma[J]. Nature 516(7530):254–258PubMedPubMedCentralCrossRef
84.
Dou H, Chen X, Huang Y et al (2017) Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia[J]. Genes Chromosomes Cancer 56(2):135–146PubMedCrossRef
85.
Potter N, Jones L, Blair H et al (2019) Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia[J]. Leukemia 33(4):893–904PubMedCrossRef
86.
Muppidi JR, Lu E, Cyster JG (2015) The G protein-coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination[J]. J Exp Med 212(13):2213–2222PubMedPubMedCentralCrossRef
87.
Lu E, Wolfreys FD, Muppidi JR et al (2019) S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8[J]. Nature 567(7747):244–248PubMedPubMedCentralCrossRef
88.
Brune V, Tiacci E, Pfeil I et al (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis[J]. J Exp Med 205(10):2251–2268PubMedPubMedCentralCrossRef
89.
He Y, Gallman AE, Xie C et al (2022) P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance[J]. J Exp Med 219(1)
90.
Chang A, Henderson SG, Brandt D et al (2011) In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis[J]. J Immunol 186(3):1849–1860PubMedCrossRef
91.
Caielli S, Veiga DT, Balasubramanian P et al (2019) A CD4(+) T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate[J]. Nat Med 25(1):75–81PubMedCrossRef
92.
Zhao LD, Liang D, Wu XN et al (2017) Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus[J]. Cell Mol Immunol 14(10):842–849PubMedCrossRef
93.
Kiso K, Yoshifuji H, Oku T et al (2017) Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients[J]. PLoS One 12(9):e184738
94.
Kim AR, Han D, Choi JY et al (2020) Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) T(H) cells suppresses the progression of pemphigus vulgaris[J]. J Allergy Clin Immunol 146(5):1070–1079PubMedCrossRef
95.
Wang Y, Zhang S, Liang Z et al (2019) Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation[J]. Mol Immunol 114:72–80PubMedCrossRef
96.
Elia G (2015) Dermatomyositis and chemokines[J]. Clin Ter 166(2):e118–e121PubMed
97.
Fujiyama T, Ito T, Ogawa N et al (2014) Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis[J]. Clin Exp Immunol 177(1):110–120PubMedPubMedCentralCrossRef
98.
Xing R, Liu F, Yang Y et al (2018) GPR54 deficiency reduces the Treg population and aggravates experimental autoimmune encephalomyelitis in mice[J]. Sci China Life Sci 61(6):675–687PubMedCrossRef
99.
Truong KL, Schlickeiser S, Vogt K et al (2019) Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4(+) memory T cells[J]. Nat Commun 10(1):2263PubMedPubMedCentralCrossRef
100.
Onozawa Y, Fujita Y, Kuwabara H et al (2012) Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro[J]. Eur J Pharmacol 683(1–3):325–331PubMedCrossRef
101.
Robert R, Mackay CR (2018) Gαs-coupled GPCRs GPR65 and GPR174. Downers for immune responses[J]. Immunol Cell Biol 96(4):341–343
102.
Lassen KG, McKenzie CI, Mari M et al (2016) Genetic coding variant in GPR65 alters lysosomal pH and links lysosomal dysfunction with colitis risk[J]. Immunity 44(6):1392–1405PubMedPubMedCentralCrossRef
103.
Wirasinha RC, Vijayan D, Smith NJ et al (2018) GPR65 inhibits experimental autoimmune encephalomyelitis through CD4(+) T cell independent mechanisms that include effects on iNKT cells[J]. Immunol Cell Biol 96(2):128–136PubMedCrossRef
104.
Xiong Y, Piao W, Brinkman CC et al (2019) CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration[J]. Sci Immunol 4(33)
105.
Ogretmen B (2018) Sphingolipid metabolism in cancer signalling and therapy[J]. Nat Rev Cancer 18(1):33–50PubMedCrossRef
106.
Chaudhry BZ, Cohen JA, Conway DS (2017) Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis[J]. Neurotherapeutics 14(4):859–873PubMedPubMedCentralCrossRef
107.
Pérez-Jeldres T, Tyler CJ, Boyer JD et al (2019) Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK Inhibitors and S1PR Agonists[J]. Front Pharmacol 10:212PubMedPubMedCentralCrossRef
108.
Sukocheva OA, Furuya H, Ng ML et al (2020) Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target[J]. Pharmacol Ther 207:107464
109.
Cartier A, Hla T (2019) Sphingosine 1-phosphate: lipid signaling in pathology and therapy[J]. Science 366(6463)
110.
Huwiler A, Zangemeister-Wittke U (2018) The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives[J]. Pharmacol Ther 185:34–49PubMedCrossRef
111.
Hargreaves DC, Hyman PL, Lu TT et al (2001) A coordinated change in chemokine responsiveness guides plasma cell movements[J]. J Exp Med 194(1):45–56PubMedPubMedCentralCrossRef
112.
Hao H, Nakayamada S, Yamagata K et al (2020) Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus[J]. Arthritis Rheumatol
113.
Wang Z, Zhao M, Yin J et al (2020) E4BP4-mediated inhibition of T follicular helper cell differentiation is compromised in autoimmune diseases[J]. J Clin Invest 130(7):3717–3733PubMedPubMedCentralCrossRef
114.
Liu C, Wang D, Song Y et al (2018) Increased circulating CD4(+)CXCR5(+)FoxP3(+) follicular regulatory T cells correlated with severity of systemic lupus erythematosus patients[J]. Int Immunopharmacol 56:261–268PubMedCrossRef
115.
Cao G, Wang P, Cui Z et al (2020) An imbalance between blood CD4(+)CXCR5(+)Foxp3(+) Tfr cells and CD4(+)CXCR5(+)Tfh cells may contribute to the immunopathogenesis of rheumatoid arthritis[J]. Mol Immunol 125:1–8PubMedCrossRef
116.
Zheng J, Wang T, Zhang L et al (2017) Dysregulation of circulating Tfr/Tfh ratio in primary biliary cholangitis[J]. Scand J Immunol 86(6):452–461PubMedCrossRef
117.
Kataoka K, Nagata Y, Kitanaka A et al (2015) Integrated molecular analysis of adult T cell leukemia/lymphoma[J]. Nat Genet 47(11):1304–1315PubMedCrossRef
118.
119.
Döring Y, Noels H, van der Vorst E et al (2017) Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity: evidence from mouse and human studies[J]. Circulation 136(4):388–403PubMedPubMedCentralCrossRef
120.
Scholten DJ, Canals M, Wijtmans M et al (2012) Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3[J]. Br J Pharmacol 166(3):898–911PubMedPubMedCentralCrossRef
121.
122.
Adlere I, Caspar B, Arimont M et al (2019) Modulators of CXCR4 and CXCR7/ACKR3 function[J]. Mol Pharmacol 96(6):737–752PubMedCrossRef
123.
Tan Q, Zhu Y, Li J et al (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex[J]. Science 341(6152):1387–1390PubMedCrossRef
124.
125.
Rizeq B, Malki MI (2020) The Role of CCL21/CCR7 chemokine axis in breast cancer progression[J]. Cancers (Basel) 12(4)
126.
Salem A, Alotaibi M, Mroueh R et al (2021) CCR7 as a therapeutic target in cancer[J]. Biochim Biophys Acta Rev Cancer 1875(1):188499
127.
Braden K, Giancotti LA, Chen Z et al (2020) GPR183-oxysterol axis in spinal cord contributes to neuropathic pain[J]. J Pharmacol Exp Ther 375(2):367–375PubMedCrossRef
128.
Misselwitz B, Wyss A, Raselli T et al (2021) The oxysterol receptor GPR183 in inflammatory bowel diseases[J]. Br J Pharmacol 178(16):3140–3156PubMedCrossRef
129.
Kjaer V, Ieremias L, Daugvilaite V et al (2021) Discovery of GPR183 agonists based on an antagonist scaffold[J]. ChemMedChem
Metadaten
Titel
Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases: from Basic Research to Clinical Trials
verfasst von
Pengpeng Cao
Ming Yang
Christopher Chang
Haijing Wu
Qianjin Lu
Publikationsdatum
08.06.2022
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2022
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-022-08936-y

Weitere Artikel der Ausgabe 3/2022

Clinical Reviews in Allergy & Immunology 3/2022 Zur Ausgabe

ReviewPaper

Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management

OriginalPaper

Serum Biomarkers for Autoimmune Hepatitis Type 1: the Case for CD48 and a Review of the Literature

ReviewPaper

The Genetics of Eczema Herpeticum

ReviewPaper

Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases

ReviewPaper

Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis

ReviewPaper

A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise